# Inga Deakin

> Inga Deakin is a Series A investor at Molten Ventures (Raleigh) backing Health Care and mHealth. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Molten Ventures](https://shizune.co/investors/profile/draper-esprit)
- Location: Raleigh, United States
- Total investments: 9
- Last investment: Jul 2026
- Lead investor: 78%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/in/ingadeakin
- X (Twitter): http://twitter.com/ingadeakin
- Website: https://x.com/ingadeakin

Inga Deakin is a Series A investor at Molten Ventures in Raleigh focused on Health Care and mHealth. Inga is an Analyst in the Healthcare Ventures team evaluating investments across therapeutics, medical devices and healthcare. She also works with the Technology Transfer team investigating commercialisation and development opportunities. Inga joined Innovations in April 2011 from the technology transfer and business development team at the RoyalVeterinary College in London. She currently sits on the Members Services committee of PraxisUnico, the UK’s representative organisation for research commercialisation professionals. She completed a DPhil and an MSc in Neuroscience from the University of Oxford, sponsored by the Wellcome Trust, and has a degree in Natural Sciences from the University of Cambridge.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 56% |
| mHealth | 2 | 22% |
| Personal Health | 2 | 22% |
| Health Diagnostics | 2 | 22% |
| Artificial Intelligence | 2 | 22% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 33% |
| Series B | 2 | 22% |
| Seed | 1 | 11% |
| Series C | 1 | 11% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 3 | 33% |
| Spain | 1 | 11% |
| Ireland | 1 | 11% |
| Switzerland | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Qureight | Qureight is an imaging analytics company. It also aims to develop a new improved and streamlined version of its analytical platform – harnessing the ability of AI and advanced processing tools to gain new insights into respiratory diseases such as Idiopathic Pulmonary Fibrosis (IPF) and lung cancer. | $20M | Series B | Jul 29, 2026 |  |
| IMU Biosciences | IMU is a discovery engine mapping the immune system to advance precision medicine. | $38.4M | Series A | Jun 01, 2026 |  |
| Hilo | Founded in Switzerland in May 2018 out of a passion to turn insights into action in the fight against hypertension, Aktiia’s groundbreaking medical technology provides people and their physicians comprehensive insights into blood pressure patterns that will inform the diagnosis and management of hypertension. Now available in the United Kingdom,Aktiia has received its CE Mark as a Class IIa medical device - signifying that the device has been assessed to meet high safety, health and environmental protection requirements in Europe. To learn more, visit Aktiia.com. | $42M | Series B | May 01, 2025 |  |
| Deciphex | Founded in 2017, Deciphex aims to transform diagnostic workflows through AI-powered digital pathology to improve patient outcomes worldwide. Its two flagship platforms target distinct markets: Diagnexia connects global subspecialty pathologists for rapid diagnostics and backlog reduction, while Patholytix accelerates drug development throughoptimized preclinical safety assessments. By automating routine tasks, these platforms enable pathologists to focus on complex cases while delivering faster, more reliable diagnoses. Through this combination of AI innovation and clinical expertise, Deciphex is advancing both healthcare delivery and therapeutic development. | $32.1M | Series C | Jan 07, 2025 |  |
| Anima | Anima's online patient triage speeds up the clinical workflow 10x and allows providers to deliver the right care for patients within 24 hours.Millions of patients with serious problems are missed and die every year because there isn’t adequate information flow between medical appointments. Patients submit their problems and requests onAnimainstead of waiting for an appointment, and Anima sends an actionable report to their provider with trends, risks and recommendations. | $12M | Series A | Mar 19, 2024 |  |
| Hilo | Founded in Switzerland in May 2018 out of a passion to turn insights into action in the fight against hypertension, Aktiia’s groundbreaking medical technology provides people and their physicians comprehensive insights into blood pressure patterns that will inform the diagnosis and management of hypertension. Now available in the United Kingdom,Aktiia has received its CE Mark as a Class IIa medical device - signifying that the device has been assessed to meet high safety, health and environmental protection requirements in Europe. To learn more, visit Aktiia.com. | $30.7M | Series A | Feb 27, 2024 |  |
| IMU Biosciences | IMU is a discovery engine mapping the immune system to advance precision medicine. | $14.6M | Series A | Jan 24, 2024 |  |
| Oliva Health | Oliva Therapy is an online therapy for busy people. It makes mental healthcare a natural part of modern daily life by removing the fear and uncertainty from the clinical, complex process of seeking care. Make real progress towards goals with expert-curated therapists, personalized matching by certified experts, focused one-hour sessions, and ahassle-free online experience.It was founded in 2020 and is based in Barcelona, Spain. | $5.4M | Seed | Jun 22, 2023 |  |
| Hilo | Founded in Switzerland in May 2018 out of a passion to turn insights into action in the fight against hypertension, Aktiia’s groundbreaking medical technology provides people and their physicians comprehensive insights into blood pressure patterns that will inform the diagnosis and management of hypertension. Now available in the United Kingdom,Aktiia has received its CE Mark as a Class IIa medical device - signifying that the device has been assessed to meet high safety, health and environmental protection requirements in Europe. To learn more, visit Aktiia.com. | $17.5M | Series A | Nov 02, 2021 |  |

9 of 9 investments shown.

## Co-investors
- [redalpine](https://shizune.co/investors/profile/redalpine-venture-partners) — VC Fund, 3 deals together
- [Translink Capital](https://shizune.co/investors/profile/translink-capital) — VC Fund, 3 deals together
- [Verve Ventures](https://shizune.co/investors/profile/verve-ventures) — VC Fund, 3 deals together
- [415 Capital](https://shizune.co/investors/profile/415-capital-management) — VC Fund, 2 deals together
- [Hargreave Hale Aim VCT](https://shizune.co/investors/profile/hargreave-hale-aim-vcts) — VC Fund, 2 deals together
- [Khosla Ventures](https://shizune.co/investors/profile/khosla-ventures) — VC Fund, 2 deals together

## About Molten Ventures

VC Fund · London, United Kingdom

Molten Ventures is a leading British venture capital firm backing Europe’s highest-growth private technology companies. Our expert investment team stay ahead of the curve, identifying transformative trends and next-generation companies before they break through. We combine multiple pools of capital to invest at all stages of the businesslifecycle—from seed and early stage to growth and late stage—focusing on disruptive sectors like Spacetech, Fintech, and AI. Our strategy is simple: back bold ideas, scale them with capital and expertise, and unlock high-value exits—whether through strategic acquisitions, trade buy-outs, or IPOs. Since our 2016 IPO, we’ve delivered strong realised returns, reinvesting into the next wave of innovation—creating a virtuous cycle of growth and value.

5 contacts available at Molten Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Alan Duncan | Venture Partner | https://shizune.co/investors/profile/alan-duncan |
| David Cummings | Partner | https://shizune.co/investors/profile/david-cummings-2 |
| George Chalmers | Principal | https://shizune.co/investors/profile/george-chalmers |
| Inga Deakin | Principal | https://shizune.co/investors/profile/inga-deakin |
| John Marsh | Senior Partner, Venture Capital | https://shizune.co/investors/profile/richard-marsh |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Inga Deakin invest in?

Inga Deakin invests primarily in Health Care, mHealth and Personal Health startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Inga Deakin last invest?

The most recent investment recorded for Inga Deakin closed in Jul 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co